|Bid||2,041.00 x 346500|
|Ask||2,045.00 x 57900|
|Day's Range||2,028.00 - 2,088.00|
|52 Week Range||1,481.00 - 2,160.00|
|PE Ratio (TTM)||6,679.74|
|Earnings Date||Nov 14, 2018 - Nov 21, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
The Zacks Analyst Blog Highlights: American River, BG Staffing, Evolution Petroleum, Kamada and Farmers & Merchants
Kamada (KMDA) delivered earnings and revenue surprises of 55.56% and 14.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rehovot, Israel-based company said it had profit of 14 cents. The biopharmaceutical posted revenue of $33.8 million in the period. Kamada shares have climbed 22 percent since ...
Total Revenues for Second Quarter were $33.8 Million, a 4% Increase Over Second Quarter of 2017 Total Revenues for First Half of 2018 were $51.3 Million, a 16% Increase Over First Half of 2017 Gross Profit ...
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter and six months ended June 30, 2018, prior to the open of the U.S. financial markets on Tuesday, August 7, 2018. Kamada management will host an investment community conference call on Tuesday, August 7 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-263-0877 (from within the U.S.), 1809 212 883 (from Israel), or 646-828-8143 (International) and entering the conference identification number: 4166824.
The Company requested scientific advice (protocol assistance) from the CHMP following the results of the previous Phase 2/3 (EU) and Phase 2 (US) studies conducted by the Company with respect to a proposed subsequent Phase 3 study design. The CHMP notified the Company that it concurs with the overall design of the proposed study, including its objectives, patient population, proposed endpoints and their clinical importance, and the safety monitoring plan.
“We are excited to present the data from our Phase 2 trial of AAT in newly diagnosed T1D patients at such a prestigious medical conference,” said Amir London, Kamada’s Chief Executive Officer. “Based on the results generated to date, and feedback received from the medical community, we believe that further studies in a larger population are warranted.
On a per-share basis, the Ness Ziona, Israel-based company said it had profit of 3 cents. The biopharmaceutical posted revenue of $17.4 million in the period. Kamada expects full-year revenue in the range ...
Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.
On a per-share basis, the Ness Ziona, Israel-based company said it had net income of 16 cents. The biopharmaceutical posted revenue of $35.7 million in the period. For the year, the company reported net ...
Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Kamada Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
The Ness Ziona, Israel-based company said it had a loss of 1 cent per share. Earnings, adjusted for stock option expense, were less than 1 cent on a per-share basis. The biopharmaceutical posted revenue ...